Systemic and Lung Inflammation in 2 Phenotypes of Chronic Obstructive Pulmonary Disease

Izquierdo, José Luis; Almonacid, Carlos; Parra, T.; Pérez, Jaime

doi:10.1016/s1579-2129(06)60542-9

Cited by 26 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some recent studies demonstrate differences in pulmonary and systemic markers associated to emphysema and chronic bronchitis. In contrast with our results, other authors suggest that in COPD patients with emphysematous phenotype the infl ammatory response and oxidative stress were reduced when compared with chronic bronchitis [30]. More studies are needed to clarify the mechanisms involved in infl ammatory response and oxidant/antioxidant balance in different clinical phenotypes of COPD patients.…”

Section: Discussioncontrasting

confidence: 99%

Oxidative Stress, Antioxidant Status and Inflammation in Chronic Bronchitis and Pulmonary Emphysema

Cristóvão¹,

Cristóvão²,

Nogueira³

et al. 2017

Arch Pulmonol Respir Care

View full text Add to dashboard Cite

Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by a complex range of pathological changes including both pulmonary and systemic effects. Several mechanisms contribute to the variable intermediate and clinically relevant disease phenotypes, such as chronic bronchitis and emphysema, and systemic disease. The molecular mechanisms associated to the pathogenesis of COPD are not yet clearly understood.Objective: The aim of this study was to evaluate oxidant/antioxidant balance and the systemic infl ammation in chronic bronchitis and pulmonary emphysema COPD patients. Methods:We analyzed COPD patients divided in 2 groups: chronic bronchitis and emphysema. Healthy volunteers without lung disease were used as control group. Results:We observed a signifi cant (P<0,05) increase in the levels of plasma malondialdehyde (MDA), a marker of oxidative stress, an increase in the circulating C-reactive protein (CRP), used as a biomarker of systemic infl ammation, and a decrease in antioxidant defense in COPD patients with emphysema when compared with COPD patients with chronic bronchitis.Conclusion: Althought our results should be regarded as preliminary they indicate a disturbance in oxidant/antioxidant status and systemic infl ammatory response associated to COPD patients. The differences observed were more evident in emphysematous phenotype.

show abstract

Section: Discussioncontrasting

confidence: 99%

Oxidative Stress, Antioxidant Status and Inflammation in Chronic Bronchitis and Pulmonary Emphysema

Cristóvão¹,

Cristóvão²,

Nogueira³

et al. 2017

Arch Pulmonol Respir Care

View full text Add to dashboard Cite

show abstract

“…IZQUIERDO et al [4] described lower concentrations of IL-8 in EBC from emphysematous subjects (0.34 pg?mL -1 ), compared with chronic bronchitics (2.32 pg?mL -1 ) and controls (3.32 pg?mL -1 ). ZIHLIF et al [6] suggested that IL-8 concentrations were undetectable in both children with primary ciliary dyskinesia and controls.…”

mentioning

confidence: 99%

“…Concentrations reported in stable COPD range from a median value of 10.6 pg?mL -1 [3] to 100.6 pg?mL -1 [1]. IZQUIERDO et al [4] reported LTB 4 concentrations at f1.1 pg?mL -1 , despite suggesting that the samples below the LLD were recorded as undetectable (the LLD specified by the assay manufacturers was 13 pg?mL -1 ). Limited data is available concerning assay validation at these low levels, although LEUNG et al [5] suggested that the assay is not reproducible at the concentrations found in EBC.…”

mentioning

confidence: 99%

“…Limited data is available concerning assay validation at these low levels, although LEUNG et al [5] suggested that the assay is not reproducible at the concentrations found in EBC. Measurement of LTB 4 by mass spectroscopy found that LTB 4 could be detected in patients with asthma who were not on therapy (LLQ given as lowest calibrator; 100 pg?mL -1 ). Conversely, PANCHAUD et al [3] suggested that the calibration curve for the assay is linear between 165-990 pg?mL -1 ; thus, quantification should be less robust outside this range.…”

mentioning

confidence: 99%

“…The assays under investigation were: commercial ELISAs for LTB 4 (GE Healthcare Life Sciences, Little Chalfont, UK and Cayman Chemical Company) and for IL-8 and SLPI (R&D Systems Europe Ltd, Abingdon, UK); an in-house ELISA for AAT; and a chromogenic activity assay for MPO. In addition, results in EBC were compared with those found in matched, spontaneous, sol phase sputum samples from the same patient on the same day, to determine whether the EBC level reflected the results of airway secretions.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Validation of assays for inflammatory mediators in exhaled breath condensate

Bayley¹,

Abusriwil²,

Ahmad³

et al. 2008

Eur Respir J

View full text Add to dashboard Cite

The use of exhaled breath condensate (EBC) as a tool for noninvasive assessment of lung inflammation is becoming commonplace. Many authors use commercial ELISA kits to measure inflammatory mediators within EBC. However, the very low concentrations of mediators within EBC are often below the commercially validated concentration range of the relevant ELISA and crucially below the linear part of the sigmoid standard curve. The present study seeks to validate a series of assays for use in EBC and to compare the results in EBC with those from matched sol phase sputum samples.The following mediators were measured by ELISA: leukotriene (LT)B 4 , interleukin (IL)-8, secretory leukoprotease inhibitor and a 1 -antitrypsin (AAT). Myeloperoxidase was measured by chromogenic substrate assay.Mediator concentrations reached the lower limit of quantification in only one assay (AAT) in 19.6% of subjects, while mediator concentrations reached the lower limit of detection in three assays (LTB 4 , IL-8 and AAT in 31, 6.5 and 61% of subjects, respectively). No significant correlations were present between any mediators in EBC and sol phase sputum.The results of the present study indicate that care must be exercised when interpreting mediator measurements in exhaled breath condensate and that assays must be validated at concentrations relevant to those found within the biological fluid.

show abstract

Valoración de la EPOC: regreso al futuro

Alonso

2010

Archivos de Bronconeumología

View full text Add to dashboard Cite

Systemic and Lung Inflammation in 2 Phenotypes of Chronic Obstructive Pulmonary Disease

Cited by 26 publications

References 24 publications

Oxidative Stress, Antioxidant Status and Inflammation in Chronic Bronchitis and Pulmonary Emphysema

Oxidative Stress, Antioxidant Status and Inflammation in Chronic Bronchitis and Pulmonary Emphysema

Validation of assays for inflammatory mediators in exhaled breath condensate

Valoración de la EPOC: regreso al futuro

Contact Info

Product

Resources

About